Acadia Pharmaceuticals Inc. (ACAD) Q4 2023 Earnings Results

Acadia Pharmaceuticals Misses on EPS, Stock Up 1.78%

Acadia Pharmaceuticals reported an EPS of $0.28, which was below expectations, leading to a slight stock increase of 1.78%. Investors may have reacted positively to management's focus on future clinical trials despite the EPS miss. The lack of revenue data and guidance leaves some uncertainty about the company's near-term performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.28	N/A	-12.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautiously optimistic outlook, emphasizing their commitment to advancing clinical programs. They did not provide specific guidance for the upcoming quarters.

Management expressed confidence in the ongoing development of their pipeline.

They highlighted the importance of upcoming clinical trials.

The team is focused on maintaining operational efficiency.

Acadia Pharmaceuticals Misses on EPS, Stock Up 1.78%

Key numbers

Management commentary

Acadia Pharmaceuticals Inc.

More earnings this week

Acadia Pharmaceuticals Misses on EPS, Stock Up 1.78%

Key numbers

Management commentary